90% effective RSV shot Beyfortus (nirsevimab) exceeds clinical trial expectations in preventing hospitalizations in babies.

Real-world data shows that the RSV shot, Beyfortus (nirsevimab), is 90% effective in preventing hospitalizations in babies. This exceeds the expected 79%-81% prevention of medical care for RSV infection and hospitalizations in clinical trials. The shot is recommended for infants under 8 months during their first RSV season, as RSV is the leading cause of hospitalization in young children.